Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAST phase 3 trial of OPT-302 plus aflibercept in neovascular age-related macular degeneration
NL-OMON54023Phase 3Recruiting
- Sponsor
- Opthea Limited
- Start
- Jan 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sozinibercept and aflibercept in exudative macular degeneration (3 arms), sponsored by Opthea Limited. Primary endpoint: Mean change in ETDRS best corrected visual acuity letters. Started Jan 2022; status: recruiting.
02
Drugs
soziniberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON54023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54023.